Artificial Intelligence
Visteon Announces microZone High-Performance Display Technology at CES 2020
LAS VEGAS, Jan. 06, 2020 (GLOBE NEWSWIRE) — Visteon Corporation (Nasdaq: VC), a leading automotive cockpit electronics technology company, today announced its breakthrough microZone™ display technology that offers significantly higher graphics performance than traditional LCD displays.
This new, patent-pending high-dynamic range (HDR) display technology offers high contrast and brightness and wide color gamut that enables automotive displays to achieve parity with consumer mobile devices with life-like imaging capability.
Designed to accelerate the development and commercialization of more energy-efficient, cost-effective digital display solutions, microZone is considered the first automotive display to offer superior optical performance without sacrificing automotive reliability. Since it is based on mature LCD technology, it passes rigorous automotive qualification requirements without susceptibility to burn-in.
“Next-generation automotive cockpit displays need optical performance that is competitive with mobile devices that consumers have come to expect,” said Sachin Lawande, president and CEO, Visteon. “MicroZone is the first display technology that offers premium optical performance at a competitive price point for automakers, without sacrificing reliability or life-span. In that sense, microZone is an effective alternative to OLED for automakers.”
MicroZone offers these next-generation display performance requirements.
- Wide Color Gamut: Today’s automotive displays achieve 75-85% of the NTSC (National Television System Committee) color space. MicroZone can render more saturated colors, up to 110% NTSC. A wider color gamut enables microZone technology to reproduce a greater range of the visible color spectrum, and is compliant with the DCI-P3 color standard for HD.
- High Contrast Ratio: Legacy LCD contrast ratio maxes out at approximately 1,500:1, and black is never really black. The microZone contrast ratio is at least 100,000:1, which is about 65-70 times higher than a typical LCD screen.
- High Brightness: With OLED technology, displays max out at approximately 600 candelas per square meter (brightness level). By comparison, microZone can achieve brightness comparable to a traditional LCD technology.
MicroZone can meet these performance targets at a power consumption on par with traditional LCD technology due to key enabling innovations developed in-house at Visteon.
“MicroZone surpasses traditional display technologies across several critical categories, including color gamut, contrast and brightness levels,” said Qais Sharif, Visteon vice president, display product line. “This is especially important as vehicle manufacturers look for new ways to reduce power consumption in the cockpit without compromising color contrast, quality and brightness.”
At CES® 2020, Visteon will host demonstrations of microZone at its booth (Central Plaza, Pavilion 13), where it will also showcase solutions to speed the transition to an all-digital vehicle cockpit and, ultimately, autonomous driving. From fully reconfigurable instrument clusters and the latest-generation, high-definition (HD) digital display technologies to driver monitoring, ADAS integration and a virtualized instrument cluster domain, Visteon products and solutions underpin the increasing shift toward connected cars and autonomous vehicles.
About Visteon
Visteon is a global technology company that designs, engineers and manufactures innovative cockpit electronics and connected car solutions for the world’s major vehicle manufacturers. Visteon is driving the smart, learning, digital cockpit of the future, to improve safety and the user experience. Visteon is a global leader in cockpit electronic products including digital instrument clusters, information displays, infotainment, head-up displays, telematics, SmartCore™ cockpit domain controllers, and the DriveCore™ autonomous driving platform. Visteon also delivers artificial intelligence-based technologies, connected car, cybersecurity, interior sensing, embedded multimedia and smartphone connectivity software solutions. Headquartered in Van Buren Township, Michigan, Visteon has approximately 10,000 employees at more than 40 facilities in 18 countries. Visteon had sales of approximately $3 billion in 2018. Learn more at www.visteon.com.
Follow Visteon:
https://www.linkedin.com/company/visteon/?trk=vsrp_companies_res_photo&trkInfo=VSRPsearchId:522343161373310041683,VSRPtargetId:2865,VSRPcmpt:primary
https://twitter.com/visteon
https://www.facebook.com/VisteonCorporation
http://www.slideshare.net/VisteonCorporation
https://www.instagram.com/visteon/
https://mp.weixin.qq.com/?lang=en_US
https://m.weibo.cn/u/6605315328
http://i.youku.com/u/UNDgyMjA1NjUxNg==?spm=a2h0k.8191407.0.0
Contacts:
Media:
Jim Fisher
734-417-6184 (mobile)
[email protected]
April Li
(86) 021-3325 3098
[email protected]
Investors:
Kris Doyle
734-710-7893
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe80e8d3-523e-4c24-b7e0-26959322dde7
Artificial Intelligence
Ancoris Recognised as Top Place to Work for Second Year Running by The Sunday Times
Ancoris recognised for fostering a sense of empowerment and respect within the workplace91% of Ancoris employees feel empowered at work93% of employees say that are treated with respectLONDON, May 21, 2024 /PRNewswire/ — Ancoris, a UK-based Google Cloud services provider, has been named a Top Medium Business in The Sunday Times 2024 Best Places to Work list. The accolade has been awarded for the second year in a row, and recognises Ancoris’ focus on DEI; its commitment to empowerment, reward, and recognition; and its wellbeing policies and frameworks.
“I am so pleased to see Ancoris recognised, once again, as a top place to work!” says Andre Azevedo, Ancoris CEO. “Ancoris is a place where we try our best to foster collaboration, empowerment, innovation, and respect – so to have our employees echo this and respond in the way they have is amazing.”
The Sunday Times survey captured Ancoris employees’ responses in a number of categories: Reward and Recognition, Information Sharing, Empowerment, Wellbeing, Instilling Pride, and Job Satisfaction. The independently managed survey showed Ancoris scoring “excellent” across all six engagement categories, with top scores in Empowerment, Wellbeing, Reward & Recognition. In response, 93% of employees say they are treated with respect; 92% feel trusted and able to make decisions; and 91% of employees feel empowered at work.
“We’ve seen a lot of change over the last 12 months. The rise of Generative AI has caused shifts in our market and economic conditions are causing customers to really qualify where they make technology investments. These pivots undoubtedly have an impact on our employees and how people feel at work,” Azevedo continues. “I truly believe, however, the innovative work we are doing for our customers has helped us maintain and create an even stronger sense of collaboration and pride for our team members. We’re lucky to have so many smart people within our business, so continuing to give them interesting, challenging, and rewarding problems to solve for our customers is really key.”
About AncorisAncoris is a leading Google Cloud Services Provider, headquartered in the UK, on a mission to become the most innovative Google Cloud partner in the ecosystem. Ancoris leverages its strong problem solving skills and continuous improvement approach to help customers become AI Native and stay ahead of their competition. Ancoris has extensive experience in Google Cloud technologies helping enterprises integrate AI-native solutions into their business through expertise in Data & AI, Application and Infrastructure Modernisation, Workspace, and Maps. Ancoris was recognized as a Rising Star for Data, Analytics, and Machine Learning in the ISG Provider™ Lens for Google Cloud Partner Ecosystem in 2022 and 2023 consecutively, and awarded Google Cloud’s 2024 EMEA Public Sector Partner of the Year award. Ancoris employs the best in the business and was named in the Top 10 Sunday Times Best Places to Work 2023, and a Top Place to Work in 2024.
Contact: Holly [email protected]
Photo – https://mma.prnewswire.com/media/2417995/Ancoris_Sunday_Times.jpgLogo – https://mma.prnewswire.com/media/2099949/4717512/Ancoris_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times-302151325.html
Artificial Intelligence
Department of Health – Abu Dhabi Partners with Roche Pharmaceuticals Middle East to Elevate Research, Clinical Trials, and Real-World Data
ABU DHABI, UAE, May 21, 2024 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Roche Pharmaceuticals Middle East during Abu Dhabi Global Healthcare Week (ADGHW). Under the MoU, the two entities will advance critical research using real-world data to study and assess the spinal muscular atrophy burden in Abu Dhabi, as well as assessing potential conduction of research and the facilitation of real-world data collection to monitor Duchenne Muscular Dystrophy (DMD) disease.
In the presence of Dr. Rashed Alsuwaidi, the Executive Director of the Healthcare Workforce Planning Sector at DoH and Michael Oberreiter, Head of Global Access at Roche Pharmaceuticals, the MoU was signed by Dr. Asma Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE.
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the at DoH said: “Abu Dhabi has a track record of excellence and fast-growing, future-forward, data-enabled services. Serving as a hub for healthcare data, Abu Dhabi’s substantial computing power enables it to harness the potential within this data, transforming it into valuable information. This, in turn, allows us to innovate and develop novel approaches to shift healthcare towards prediction, prevention, and treatment, thereby accelerating the future of healthcare, not only for Abu Dhabi but for the global community. Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as expand access to quality care for patients around the world.”
The two entities will work together to support the evolution of real-world data collection frameworks in Abu Dhabi. Enhancing DoH’s ability to track and monitor outcomes of therapies will support DoH in making informed clinical and policy decisions for better optimisation of patient outcomes. Furthermore, DoH and Roche will strengthen the research network across Abu Dhabi and improve accrual for potential clinical trials.
Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE said: “This MoU underscores our collaboration with the DoH which is fuelled by a shared vision of harnessing the power of data to drive informed decision-making within the healthcare system. Data-driven healthcare systems hold immense potential to revolutionise patient care and outcomes. Through the generation, utilisation, and realisation of data, healthcare professionals and policymakers can unlock valuable insights, identify trends, and make evidence-based decisions. This data-driven approach enables us to optimise resource allocation, personalise treatment approaches, and ultimately achieve better patient outcomes. By harnessing the full potential of data, we can improve the overall efficiency and effectiveness of the healthcare system, ensuring that every patient receives the highest quality of care tailored to their specific needs. We are sincerely grateful for the trust, confidence, and empowerment the DoH has placed in establishing this effective public-private partnership with Roche in the UAE.”
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council, ADGHW is a major government initiative by the DoH, which took place from the 13th -15th May 2024.
For more information please visit: https://www.adghw.com/
About Department of Health – Abu Dhabi (DoH):
The DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforce standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system.
For further information on DoH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.
Photo – https://mma.prnewswire.com/media/2417975/DoH_Partners_with_Roche_Pharmaceuticals.jpg
View original content:https://www.prnewswire.co.uk/news-releases/department-of-health–abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research-clinical-trials-and-real-world-data-302151316.html
Artificial Intelligence
Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality Summit Europe
Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes
BARCELONA, Spain, May 21, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that leaders from Ascendis Pharma A/S, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will be keynote speakers at Veeva R&D and Quality Summit, Europe, June 4-5 in Madrid, Spain. Life sciences professionals across the industry will come together to share how connected technologies across clinical, regulatory, safety, and quality are advancing innovations for patients.
As one of the largest gatherings of biopharma leaders in Europe, Veeva R&D and Quality Summit will bring together over 1,000 industry professionals to share learnings across more than 100 sessions. Bayer and Jazz Pharmaceuticals will join Rik Van Mol, senior vice president of Veeva Development Cloud, and Avril England, general manager of Veeva Vault, for the opening keynote to explore the future of development for new medicines and therapies.
The event’s zone keynotes include:
Ascendis and Bayer, sharing strategies to reduce costs and accelerate trials with a connected platform.Boehringer Ingelheim, detailing its shift toward data-centric regulatory information management.Novo Nordisk, showing how it uses data and AI to transform clinical research.Sanofi, explaining its innovative approach to advance quality through operational excellence.Teva, providing insight into its rapid journey from disparate safety systems into one streamlined global solution.A panel with Elpida Therapeutics CEO Terry Pirovolakis and Veeva experts will close the event with a discussion on how the industry can best accelerate the development of life-saving rare disease gene therapies.
“Connecting clinical, regulatory, safety, and quality is key to advancing the product lifecycle and delivering better outcomes for patients,” says Rik Van Mol, senior vice president of Veeva Development Cloud. “At Veeva R&D and Quality Summit, biopharma leaders can connect, exchange ideas, and share new strategies to advance the industry forward together.”
Veeva R&D and Quality Summit is open exclusively to life sciences professionals. Register and review the agenda at veeva.com/eu/Summit.
Additional InformationConnect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy WhittakerVeeva [email protected]
Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-shape-the-future-of-drug-development-at-veeva-rd-and-quality-summit-europe-302150491.html
-
Uncategorized7 days ago
Artificial intelligence tool detects sex-related differences in brain structure
-
Artificial Intelligence5 days ago
Japan Data Center Market Investment to Reach $14.48 Billion by 2028 – Watch Out Exclusive Insight on Japan & Hong Kong Data Center Market – Arizton
-
Uncategorized6 days ago
Google to roll out AI-generated summaries at top of search engine
-
Uncategorized4 days ago
Coca-Cola: The future is ‘AI meets human ingenuity’
-
Artificial Intelligence5 days ago
Strava Unveils New Chapter of Accelerated Product Development at Brand’s Flagship Event
-
Artificial Intelligence5 days ago
Data Center Colocation Market Worth USD 58.4 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
-
Artificial Intelligence4 days ago
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
-
Artificial Intelligence6 days ago
IBM Expands Qiskit, World’s Most Performant Quantum Software